CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $8.4M, lower than 95% of all stocks globally
- PositionOperating margin is -5652.4%, lower than 95% of its Biotechnology peers (median -23.8%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.47BUSDvs all stocks (USD)
Revenue (TTM)
8.40MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-0.7130xvs all stocks
52-Week Change
768.13%vs all stocks
Market Capitalization
3.47BUSDvs all stocks (USD)
Enterprise Value
2.99BUSDvs all stocks (USD)
Forward P/E
-9.54xvs Biotechnology peers
Price to Book (MRQ)
6.32xvs Biotechnology peers
Enterprise to Revenue
355.95xvs Biotechnology peers
Enterprise to EBITDA
-6.87xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-58.79%vs Biotechnology peers
Return on Equity (TTM)
-64.57%vs Biotechnology peers
Revenue (TTM)
8.40MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0820USDUpdated Jul 17, 2026Quarterly Revenue Growth
-90.00%vs Biotechnology peers
Gross Profit (TTM)
8.40MUSDvs all stocks (USD)
EBITDA (TTM)
-435.26MUSDvs all stocks (USD)
Net Income (TTM)
-237.42MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-89.99%vs Biotechnology peers
Operating Cash Flow (TTM)
-376.25MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-206.75MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 17, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
24.05MUSDFY2025 · Dec 31, 2025Operating Income
-453.80MUSDvs all stocks (USD)
Pre-tax Income
-251.89MUSDFY2025 · Dec 31, 2025Income Tax Expense
-8.56MUSDFY2025 · Dec 31, 2025Net Income
-243.32MUSDFY2025 · Dec 31, 2025EBIT
-453.80MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-638.22MUSDFY2025 · Dec 31, 2025Research & Development
386.00MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
91.86MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
14.18MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-243.32MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-393.02MUSDFY2025 · Dec 31, 2025Free Cash Flow
-393.67MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
91.05MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-243.32MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
3.50MUSDFY2025 · Dec 31, 2025Stock-based Compensation
43.52MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-186.21MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-6.04MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-4.47MUSDFY2025 · Dec 31, 2025Capital Expenditures
-653.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-209.17MUSDFY2025 · Dec 31, 2025Sale of Investments
447.95MUSDFY2025 · Dec 31, 2025Other Investing Activity
49.74MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
287.88MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
127.23MSharesUpdated Jul 17, 2026Float Shares
85.84MSharesUpdated Jul 17, 2026Shares Short
14.29MSharesUpdated Jul 17, 2026Short Ratio
8.48daysvs all stocks
Short % of Shares Outstanding
19.95%vs all stocks
% Held by Insiders
0.62%vs all stocks
% Held by Institutions
99.91%vs all stocks
Total Cash (MRQ)
522.94MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.10USDUpdated Jul 17, 2026Total Debt (MRQ)
35.66MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0629xvs Biotechnology peers
Current Ratio (MRQ)
7.51xvs Biotechnology peers
Book Value per Share (MRQ)
4.46USDUpdated Jul 17, 2026Total Assets
411.94MUSDvs all stocks (USD)
Total Current Assets
318.23MUSDFY2025 · Dec 31, 2025Total Liabilities
110.64MUSDFY2025 · Dec 31, 2025Total Non-current Assets
93.71MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
37.33MUSDFY2025 · Dec 31, 2025Total Current Liabilities
73.32MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
89.67MUSDFY2025 · Dec 31, 2025Other Short-term Investments
218.83MUSDFY2025 · Dec 31, 2025Accounts Payable
10.11MUSDFY2025 · Dec 31, 2025Short-term Debt
4.67MUSDFY2025 · Dec 31, 2025Deferred Revenue
1.46MUSDFY2025 · Dec 31, 2025Long-term Debt
32.24MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
330.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
10.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-901.88MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
301.30MUSDvs all stocks (USD)
52-Week Low
3.25USDUpdated Jul 17, 202652-Week High
31.35USDUpdated Jul 17, 202652-Week Change
768.13%vs all stocks
Beta
-0.7130xvs all stocks
50-Day MA
23.89USDUpdated Jul 17, 2026200-Day MA
18.42USDUpdated Jul 17, 2026Avg 10-Day Volume
1.68MSharesUpdated Jul 17, 2026Avg 30-Day Volume
1.69MSharesUpdated Jul 17, 2026Diluted EPS (TTM)
-1.78USDUpdated Jul 17, 2026Other Income / Expense
187.74MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -5652.4%, lower than 95% of its Biotechnology peers (median -23.8%)Significant
Operating margin: -56.52Industry median: -0.24Industry P5: -32.91Peers compared: 197
Financial Health
Altman Z-Score 12.9: safe zoneNotable
Altman Z-Score: 12.90
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $8.4M, lower than 95% of all stocks globallySignificant
Revenue (USD): 8,402,000Global P5: 30,274,777.221
Market cap is $3.47B, above the global median of $1.15BNotable
Market cap (USD): 3,471,606,615Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Ideaya Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hanmi Pharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Arcus Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hubei Jumpcan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Nhwa Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tasly Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pegbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Haemonetics Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Harbin Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow